Xenon Pharmaceuticals — Q3 2026 Earnings Summary

Xenon Pharmaceuticals submitted a New Drug Application for azetukalner to the FDA in September 2026 for the treatment of focal seizures. The company completed enrollment in its Phase 3 X-NOVA2 study for major depressive disorder, with topline data expected in December 2026. Positive Phase 1 results were reported for two novel non-opioid pain programs, XEN1701 and XEN1120, with Phase 2 studies planned for the first half of 2027. For the third quarter ended September 30, 2026, the company reported a net loss of $110.4 million and held $1.2 billion in cash, cash equivalents, and marketable securities.